The new federal health law granted FDA broad discretion to create a formal approval process for "generic" versions of biotech drugs. This Washington Legal Foundation program discussed an approval pathway for biosimilars and what's next for FDA on healthcare law implementation.
As a part of the discussion, panelists:
View a recording of the webcast.
View Kathy's presentation slides on the left.